收稿日期: 2019-03-14
网络出版日期: 2019-06-26
基金资助
国家“重大新药创制”科技重大专项基金2018ZX09301-018-004
Spectrometric analyses of larotaxel and larotaxel liposomes quantification by high performance liquid chromatography
Received date: 2019-03-14
Online published: 2019-06-26
Supported by
Supported by the National Key Grant for New Drug Innovation 2018ZX09301-018-004
李雪琦 , 李建伟 , 李秋红 , 阎妍 , 段嘉伦 , 崔一诺 , 苏展博 , 罗倩 , 许佳瑞 , 杜亚菲 , 王桂玲 , 谢英 , 吕万良 . 拉洛他赛的波谱解析及高效液相色谱法对其脂质体含量的测定[J]. 北京大学学报(医学版), 2019 , 51(3) : 467 -476 . DOI: 10.19723/j.issn.1671-167X.2019.03.014
| [1] | Vallo S, Michaelis M, Rothweiler F , et al. Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics[J]. Transl Oncol, 2015,8(3):210-216. |
| [2] | Cao YN, Zheng LL, Wang D , et al. Recent advances in microtubule-stabilizing agents[J]. Eur J Med Chem, 2018,143(1):806-828. |
| [3] | Iqbal J, Abbasi BA, Mahmood T , et al. Plant-derived anticancer agents: A green anticancer approach[J]. Asian Pac J Trop Biomed, 2017,7(12):1129-1150. |
| [4] | Metzger-Filho O, Moulin C, De Azambuja E , et al. Larotaxel: broadening the road with new taxanes[J]. Expert Opin Investig Drugs, 2009,18(8):1183-1189. |
| [5] | Ren S, Wang Y, Wang J , et al. Synjournal and biological evaluation of novel larotaxel analogues[J]. Eur J Med Chem, 2018,156(5):692-710. |
| [6] | Zhang H, Qiao Y, Li M , et al. Synjournal and cytotoxicity of two active metabolites of larotaxel[J]. Anticancer Agents Med Chem, 2016,16(7):875-880. |
| [7] | Khazir J, Mir BA, Pilcher L , et al. Role of plants in anticancer drug discovery[J]. Phytochem Lett, 2014,7(1):173-181. |
| [8] | Dieras V, Limentani S, Romieu G , et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based the-rapy[J]. Ann Oncol, 2008,19(7):1255-1260. |
| [9] | Zatloukal P, Gervais R, Vansteenkiste J , et al. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer[J]. J Thorac Oncol, 2008,3(8):894-901. |
| [10] | Sternberg CN, Skoneczna IA, Castellano D , et al. Larotaxel with cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)[J]. Oncology, 2013,85(4):208-215. |
| [11] | Robert F, Harper K, Ackerman J , et al. A phase I study oflarotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naive patients with stage IIIB or stage IV non-small cell lung cancer[J]. Cancer Chemother Pharmacol, 2010,65(2):227-234. |
| [12] | Singla AK, Garg A, Aggarwal D . Paclitaxel and its formulations[J]. Int J Pharm, 2002,235(1):179-192. |
| [13] | Che X, Shen L, Xu H , et al. Isolation and characterization of process-related impurities and degradation products in larotaxel[J]. J Pharm Biomed Anal, 2011,55(5):1190-1196. |
| [14] | Torchilin VP, Omelyanenko VG, Papisov MI , et al. Poly(ethy-lene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity[J]. Biochim Biophys Acta, 1994,1195(1):11-20. |
| [15] | Bertrand N, Wu J, Xu X , et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology[J]. Adv Drug Deliv Rev, 2014,66(24):2-25. |
| [16] | Sanna V, Pala N, Sechi M . Targeted therapy using nanotechnology: focus on cancer[J]. Int J Nanomedicine, 2014,9(1):467-483. |
/
| 〈 |
|
〉 |